Evidence map›Paper›PMID 41988866›Full record

Trial reportAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis.

Jonathan M Wilson, Jeffrey L Dage, Hui-Rong Qian, Courtney L Irelan, Hannah S Crowder, Kevin L Duffin, Mark Mintun, Dawn A Brooks, Hertzel C Gerstein, M Angelyn Bethel

Registry-linked trialAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01394952. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01394952 phase3completed

The Effect of Dulaglutide on Major Cardiovascular Events in Patients With Type 2 Diabetes: Researching Cardiovascular Events With a Weekly INcretin in Diabetes (REWIND)

Ran2011Enrolled9,901Registered outcomes6Posted comparisons8ConditionsCardiovascular Disease, Diabetes Mellitus, Type 2ArmsDulaglutide, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jonathan M WilsonEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Jeffrey L DageStark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Hui-Rong QianEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Courtney L IrelanEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Hannah S CrowderEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Kevin L DuffinEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Mark MintunEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Dawn A BrooksEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Hertzel C GersteinPopulation Health Research Institute, Hamilton, Ontario, Canada.
M Angelyn BethelEli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.

Funding

Eli Lilly and Company
6 · The paper itself

Abstract

introductionThis post hoc analysis of the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial examined associations between dulaglutide, Alzheimer's disease and related dementia (ADRD) biomarkers, and substantive cognitive impairment (SCI).

methodsParticipants (dulaglutide, n = 3741; placebo, n = 3627) completed cognitive tests and provided blood samples at baseline and 2 years, with additional cognitive tests at 5-year and final visits. Analysis of covariance and Cox models tested associations between dulaglutide, SCI, and plasma neurofilament light chain (NfL), phosphorylated tau217 (p-tau217), and glial fibrillary acidic protein (GFAP) biomarkers.

resultsDulaglutide-associated changes in biomarkers or SCI were nonsignificant overall. Participants with NfL ≥56 pg/mL had a dulaglutide-associated 2-year reduction in NfL (-27.4% vs -14.2%; p = 0.003). Participants with p-tau217 ≥25 pg/mL had a dulaglutide-associated SCI reduction (hazard ratio = 0.78; p = 0.0064). DISCUSSION: Dulaglutide reduced NfL and SCI in participants with select elevated plasma ADRD biomarkers, with limited 2-year effects on p-tau217 and GFAP. Future studies with longer follow-up should explore incretin-related cognitive changes. CLINICAL TRIAL REGISTRATION INFORMATION: NCT01394952, registered July 15, 2011.

Indexed as

Cognitive DysfunctionGlucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsAgedBiomarkersFemaleGlial Fibrillary Acidic ProteinHumansMaleNeurofilament Proteinstau ProteinsBiomarkersdulaglutideGlial Fibrillary Acidic ProteinGlucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc Fragmentsneurofilament protein LNeurofilament ProteinsRecombinant Fusion Proteinstau ProteinsAlzheimer's diseasecognitive impairmentdulaglutideglial fibrillary acidic proteinphosphorylated tau217plasma neurofilament light chain

Identifiers

PMID41988866
PMCPMC13084528

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.